Some good work there.
There are lots of assumptions, though. What probably do you give those numbers? Are peak revenue numbers really a good way to value a drug during phase 1a and 1b of a trial? Biotech peers dont seem to be able to achieve that.
Like the thought process, though.
- Forums
- ASX - By Stock
- RAC - Crystal ball gazing
Some good work there. There are lots of assumptions, though....
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.64 |
Change
-0.015(0.91%) |
Mkt cap ! $281.1M |
Open | High | Low | Value | Volume |
$1.65 | $1.66 | $1.64 | $54.86K | 33.25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17732 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.64 | 2600 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17732 | 1.630 |
1 | 708 | 1.605 |
1 | 708 | 1.580 |
1 | 2000 | 1.570 |
1 | 1279 | 1.555 |
Price($) | Vol. | No. |
---|---|---|
1.640 | 2600 | 1 |
1.645 | 2344 | 2 |
1.650 | 1057 | 1 |
1.655 | 612 | 1 |
1.665 | 60 | 1 |
Last trade - 12.44pm 29/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |